JNJ Begins Phase 3 COVID-19 Vaccine Trial, Another Headstone In Alzheimer's Graveyard, PFE On Watch

Today's Daily Dose brings you news about AC Immune's disappointing results in Alzheimer's trial, Actinium Pharma's progress in the Acute Myeloid Leukemia study, Johnson & Johnson initiating phase III trial of its COVID-19 vaccine candidate, and Pfizer's regulatory catalyst.